This article by Ana Mitrovic Jovanovic provides an in-depth exploration of Hyperbaric Oxygen Therapy (HBOT) in the context of infertility treatment, positioning it as a promising therapeutic option. Despite continuous advancements in reproductive technologies, modern infertility management still faces significant challenges.
The article outlines various factors contributing to infertility, including embryo quality, endometrial receptivity, recurrent implantation failure, ovarian reserve, and sperm quality.
A successful implantation requires the presence of a healthy blastocyst and an endometrium that has reached a specific window of receptivity—characterized by adequate oxygenation, vascularization, and the expression of diverse genetic and molecular factors essential for optimal endometrial receptivity.
To address these factors and enhance treatment outcomes for infertility patients, the article recommends HBOT—a modality that has been clinically applied for over 15 years. In this therapy, patients undergo 70-minute sessions of high-pressure oxygen exposure inside multiplace chambers, typically for 7–10 consecutive days, beginning on cycle day 2–5.
Evaluations of HBOT efficacy have yielded encouraging results, including improved endometrial oxygenation and vascularization, enhanced oocyte and embryo quality, increased responsiveness to ovarian stimulation, and higher pregnancy rates.
Moreover, HBOT demonstrates positive effects during follicular monitoring, revealing excellent endometrial thickness and trilaminar endometrial response. Endometrial quality significantly improves during HBOT-treated cycles—and this improvement persists into the following month. Although a slight increase in uterine vascular resistance was observed, this is considered an expected physiological response to HBOT. Subendometrial vascular mapping before and after treatment shows strengthened capillary networks within the endometrium—particularly evident 4–6 weeks post-HBOT.
The article posits that HBOT is a therapeutic modality leveraging oxygen at elevated pressures to improve pregnancy implantation outcomes—primarily by enhancing endometrial receptivity. If endometrial receptivity depends on appropriate growth, vascularization, and oxygenation, HBOT represents an optimal intervention.
The article also discusses HBOT’s application in male infertility. This therapy enhances sperm motility, supports spermatogenesis, and improves overall sperm function—especially when combined with high-quality sperm preparation media. Notably, the benefits of HBOT persist over time, with positive impacts on spermatogenesis and sperm DNA integrity observed 70–90 days post-treatment.
Final Thoughts
Numerous factors ultimately influence both male and female fertility—but our clinical experience indicates that HBOT can exert a positive impact on infertility treatment, improving reproductive capacity in both sexes.
The article concludes that HBOT holds considerable promise for optimizing infertility outcomes in both male and female patients, addressing multiple underlying contributors to subfertility.
ZTCloudOxy — Connecting Wellness · Empowering Life: Enabling health through technology, integrating oxygen into everyday life.
0 comments